Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2018-05-29 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC AND CELGENE EXPAND IPSC COLLABORATION TO INCLUDE ADDITIONAL CELL LINES
Regulatory Filings Classification · 100% confidence The document is a short press release dated May 29, 2018, announcing an expansion of a collaboration between Evotec and Celgene, including a $6M payment. It is characterized by a headline, a date, and boilerplate information typical of a news wire service (DGAP-News). It does not contain comprehensive financial statements (like 10-K or IR), detailed management analysis (MDA), or specific voting/dividend information. Since it is an announcement of a business development event (collaboration expansion and payment) that doesn't fit into the specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news announcements distributed via regulatory channels, or potentially a general business update. Given the options, RNS is the most appropriate catch-all for this type of corporate news release that isn't a formal financial report or specific corporate action notice.
2018-05-29 English
EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP
M&A Activity Classification · 99% confidence The document is a press release dated May 21, 2018, announcing a 'STRATEGIC ONCOLOGY PARTNERSHIP' between Evotec AG and Celgene Corporation. It details the terms, including an upfront payment and future milestones/royalties, related to a drug discovery and development collaboration. This type of announcement, detailing a significant business agreement, financing component (upfront payment), and strategic alliance, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER) or corporate governance categories (like DEF 14A, DIRS). It is a general corporate news announcement regarding a major business development. Since it is not a report itself but a news release about a partnership, and it doesn't fit other specific codes like M&A (TAR), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements transmitted via services like DGAP.
2018-05-21 English
Evotec and Celgene enter into strategic oncology partnership
Regulatory Filings Classification · 95% confidence The document is a short announcement dated May 21, 2018, labeled as 'Ad-hoc' and disclosing 'inside information acc. to Article 17 MAR'. It details a strategic partnership agreement between Evotec and Celgene regarding drug discovery in oncology, including upfront payments and potential milestones. This type of announcement, which reports on a significant corporate event (like a major partnership or transaction) outside of routine financial reporting periods (like 10-K or IR), fits best under the general category for regulatory announcements or corporate news that doesn't match a more specific category like M&A (TAR) or Financing (CAP). Since it is a specific corporate news item disclosed under MAR regulations, and it is not a transcript, earnings release, or director dealing, the most appropriate general category for non-standard regulatory news is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2018-05-21 English
Evotec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 20.06.2018 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is a formal announcement ('Bekanntmachung') from Evotec AG, dated May 14, 2018, concerning the upcoming Annual General Meeting ('Hauptversammlung') on June 20, 2018. The text explicitly details the agenda ('Tagesordnung') for this meeting. Key agenda items include the presentation of the 2017 Annual Financial Statements, voting on the discharge of management and supervisory boards, appointment of auditors for 2018, and crucially, a resolution regarding the 'Formwechselnde Umwandlung der Gesellschaft in eine Europäische Gesellschaft (SE)' (Conversion of the company into a European Company (SE)). Since the primary purpose of this filing is to formally convene the shareholders for the AGM and list the items to be voted upon, it directly relates to the Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2018-05-14 German
EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
Earnings Release Classification · 100% confidence The document is titled "EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE" and contains detailed financial figures for the first quarter (Q1) of 2018, including revenues, EBITDA, and R&D expenses. It explicitly discusses quarterly performance, confirms financial guidance for the year, and mentions an upcoming conference call to discuss these results. This content structure—a detailed report of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report. It is not merely an announcement of a report (RPA) because it contains the full substance of the results, nor is it the Annual Report (10-K). Therefore, the classification is Interim / Quarterly Report (IR). Q1 2018
2018-05-09 English
Präsentation Q1 2018
Investor Presentation Classification · 95% confidence The document is a presentation titled 'Good start for external innovation with new business mix' which outlines Q1 2018 financial highlights, business segments (EVT Execute, EVT Innovate), and strategic outlook. It contains detailed financial performance data, KPIs, and pipeline information. As it is a slide-based presentation used to communicate financial results and strategy to investors, it is classified as an Investor Presentation. Q1 2018
2018-05-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.